Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.68 |
| ▸ | PPARA | Q07869 | 9/20 | 0.68 |
| ▸ | PPARD | Q03181 | 8/20 | 0.68 |
| ▸ | CCR2 | P41597 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096741 | 0.90 | PPARG (0.67) | PPARGPPARAPPARDCCR2ACLY | |
| SCHEMBL12096838 | 0.89 | PPARG (0.57) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096716 | 0.88 | PPARG (0.67) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096644 | 0.86 | PPARG (0.70) | PPARGPPARAPPARDPTGER2TAS2R14 | |
| SCHEMBL12096917 | 0.86 | PPARG (0.53) | PPARGPPARAPPARDACLYTAS2R14 | |
| SCHEMBL12096731 | 0.85 | PPARG (0.52) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096922 | 0.85 | PPARG (0.66) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096655 | 0.84 | PPARG (0.57) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096688 | 0.83 | PPARG (0.55) | PPARGPPARAPPARDACLY | |
| SCHEMBL12096775 | 0.83 | PPARG (0.58) | PPARGPPARAPPARDACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PPARG 423/4885PPARA 564/4885PPARD 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.